{"id":"aripiprazole-fixed-dose","safety":{"commonSideEffects":[{"rate":"10-25","effect":"Akathisia"},{"rate":"10-20","effect":"Headache"},{"rate":"5-15","effect":"Anxiety"},{"rate":"5-15","effect":"Insomnia"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Weight gain"},{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Sedation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aripiprazole acts as a partial agonist at dopamine D2 receptors and serotonin 5-HT1A receptors, meaning it can both activate and inhibit these receptors depending on baseline neurotransmitter levels. This unique mechanism allows it to normalize dopaminergic and serotonergic signaling, reducing excessive dopamine activity in psychotic states while maintaining adequate dopamine function in other brain regions. The fixed-dose formulation ensures consistent therapeutic levels for improved treatment adherence.","oneSentence":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that stabilizes dopamine and serotonin neurotransmission in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:26.111Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute manic or mixed episodes)"},{"name":"Major depressive disorder (adjunctive treatment)"},{"name":"Autism spectrum disorder (irritability)"}]},"trialDetails":[{"nctId":"NCT06937476","phase":"NA","title":"Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole","status":"RECRUITING","sponsor":"Central South University","startDate":"2025-05-08","conditions":"Major Depressive Disorder (MDD), Rumination","enrollment":108},{"nctId":"NCT07024303","phase":"EARLY_PHASE1","title":"Measurement of Treatment Effects","status":"NOT_YET_RECRUITING","sponsor":"Matthew J O'Brien, PhD, BCBA-D","startDate":"2025-06-15","conditions":"Challenging Behavior, Autism Spectrum Disorder","enrollment":20},{"nctId":"NCT02357849","phase":"PHASE4","title":"Fluoxetine vs Aripiprazole Comparative Trial (FACT)","status":"TERMINATED","sponsor":"Northwell Health","startDate":"2014-07","conditions":"Attenuated Psychosis Syndrome","enrollment":9},{"nctId":"NCT01418352","phase":"PHASE3","title":"Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-08-02","conditions":"Tourette's Disorder","enrollment":83},{"nctId":"NCT02949752","phase":"PHASE4","title":"Aripiprazole as an Adjunct to Atypical Antipsychotics for Weight Reduction and Improvement in Metabolic Profile","status":"COMPLETED","sponsor":"Institute of Mental Health, Singapore","startDate":"2016-08","conditions":"Antipsychotics Weight Gain","enrollment":67},{"nctId":"NCT00509067","phase":"PHASE2","title":"Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2007-11","conditions":"Schizophrenia","enrollment":43},{"nctId":"NCT01727700","phase":"PHASE3","title":"Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2012-11","conditions":"Tourette's Disorder, Tic Disorder","enrollment":133},{"nctId":"NCT00876343","phase":"PHASE3","title":"Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2009-03","conditions":"Major Depressive Disorder","enrollment":586},{"nctId":"NCT00337571","phase":"PHASE3","title":"Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-06","conditions":"Behavioral Symptoms, Autistic Disorder","enrollment":218},{"nctId":"NCT00232687","phase":"PHASE4","title":"A Switch Study of BMS-337039 in Schizophrenic Out-patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-06","conditions":"Schizophrenia","enrollment":450},{"nctId":"NCT00580125","phase":"PHASE2","title":"Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-11","conditions":"Schizophrenia","enrollment":164},{"nctId":"NCT01488266","phase":"NA","title":"Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder","status":"UNKNOWN","sponsor":"Korea University","startDate":"2011-11","conditions":"Major Depressive Disorder","enrollment":90},{"nctId":"NCT00873795","phase":"NA","title":"Compare the Efficacy and Tolerability of the Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitors (SSRIs) Used in Major Depression","status":"COMPLETED","sponsor":"Chimei Medical Center","startDate":"2007-04","conditions":"Major Depressive Disorder","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":42,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aripiprazole"],"phase":"phase_3","status":"active","brandName":"Aripiprazole (Fixed dose)","genericName":"Aripiprazole (Fixed dose)","companyName":"Otsuka Pharmaceutical Co., Ltd.","companyId":"otsuka","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aripiprazole is a fixed-dose medication used to treat conditions such as schizophrenia, challenging behavior, autism spectrum disorder, and major depressive disorder. It works as a partial agonist at the D(2) dopamine receptor, a small molecule mechanism that is classified as a dopamine D2 receptor partial agonist.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2013-02-28T00:00:00.000Z","mah":"OTSUKA PHARM CO LTD","brand_name_local":"ABILIFY MAINTENA KIT","application_number":"NDA202971"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-04-28T00:00:00.000Z","mah":"TEVA PHARMS USA","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA078608"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-04-28T00:00:00.000Z","mah":"ALEMBIC","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA202101"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-04-28T00:00:00.000Z","mah":"TORRENT","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA201519"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-04-28T00:00:00.000Z","mah":"ALEMBIC","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA202102"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-04-28T00:00:00.000Z","mah":"TEVA PHARMS USA","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA078607"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-04-28T00:00:00.000Z","mah":"HETERO LABS LTD V","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA205064"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-04-28T00:00:00.000Z","mah":"TEVA PHARMS USA","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA078708"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-07-24T00:00:00.000Z","mah":"APOTEX","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA078583"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-08-14T00:00:00.000Z","mah":"LANNETT CO INC","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA204171"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-09-30T00:00:00.000Z","mah":"APOTEX","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA204094"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-06-17T00:00:00.000Z","mah":"AMNEAL PHARMS","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA204838"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-09-29T00:00:00.000Z","mah":"SCIEGEN PHARMS","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA206383"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-10-07T00:00:00.000Z","mah":"MACLEODS PHARMS LTD","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA204111"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-12-07T00:00:00.000Z","mah":"ACCORD HLTHCARE","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA206251"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-01-09T00:00:00.000Z","mah":"AIPING PHARM INC","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA091279"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-05-23T00:00:00.000Z","mah":"ORBION PHARMS","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA202683"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-11-13T00:00:00.000Z","mah":"OTSUKA","brand_name_local":"ABILIFY MYCITE KIT","application_number":"NDA207202"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-12-04T00:00:00.000Z","mah":"PRINSTON INC","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA205363"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-12-11T00:00:00.000Z","mah":"ORBION PHARMS","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA202547"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-04-18T00:00:00.000Z","mah":"SCIEGEN PHARMS","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA207240"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-08-28T00:00:00.000Z","mah":"SQUARE PHARMS","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA090165"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-09-19T00:00:00.000Z","mah":"RISING","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA206240"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-01-07T00:00:00.000Z","mah":"ZYDUS PHARMS","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA090472"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-01-29T00:00:00.000Z","mah":"AUROBINDO PHARMA LTD","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA210479"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-02-21T00:00:00.000Z","mah":"ALKEM LABS LTD","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA207105"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-12-26T00:00:00.000Z","mah":"VISTAPHARM LLC","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA212870"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-12-01T00:00:00.000Z","mah":"UNICHEM","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA203025"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-10-25T00:00:00.000Z","mah":"CHARTWELL RX","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA215595"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-04-27T00:00:00.000Z","mah":"OTSUKA","brand_name_local":"ABILIFY ASIMTUFII","application_number":"NDA217006"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-11-01T00:00:00.000Z","mah":"HETERO LABS LTD III","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA216150"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-03-18T00:00:00.000Z","mah":"LUPIN","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA205589"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-07-22T00:00:00.000Z","mah":"XIAMEN LP PHARM CO","brand_name_local":"OPIPZA","application_number":"NDA216655"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-12-03T00:00:00.000Z","mah":"MYLAN","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA216608"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-04-15T00:00:00.000Z","mah":"CMG PHARM CO LTD","brand_name_local":"MEZOFY","application_number":"NDA211448"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-10-22T00:00:00.000Z","mah":"QUAGEN","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA215582"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2026-02-18T00:00:00.000Z","mah":"AUROBINDO PHARMA","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA216208"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"PHARMTAK INC","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA208260"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"SUN PHARMA GLOBAL","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA078614"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"BARR LABS INC","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA078613"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"PHARMTAK INC","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA208438"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"BARR LABS INC","brand_name_local":"ARIPIPRAZOLE","application_number":"ANDA078612"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}